Overview of the drug development for Influenza A
Influenza is a contagious disease, often caused by the influenza virus. The disease generally is communicable and is commonly called as flu. Influenza is further classified into three types including influenza A, influenza B, and influenza C. The condition can cause moderate to severe illnesses while affecting all age groups. Influenza A causes more risks in young children, and elderly people with a weakened immune system. Furthermore, according to CDC, the pandemic H1N1 influenza virus had caused over 60 million Americans to become ill and led to over 270,000 hospitalization cases and about 12,500 deaths. Such rising incidences of this health conditions are likely to boost the growth of drug development for Influenza A.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for Influenza A. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Drug development for Influenza A market report: Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of Influenza A. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- ABIVAX
- Akshaya Bio
- Altimmune
- Biological Mimetics
Want a bigger picture? Try a FREE sample of this report now!
Therapeutic assessment of the drug development for Influenza A by route of administration
- Intranasal
- Intramuscular
- Oral
- Intravenous
- Parenteral
- Intramuscular + subcutaneous
- Intravenous + oral
As per this clinical trial report, most of the drug molecules are being administered through the intranasal route of administration (ROA) involving the application of the drug directly through the nasal structures.
Therapeutic assessment of the drug development for Influenza A by therapy
- Monotherapy
- Monotherapy/combination therapy
- Combination therapy
According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for Influenza A are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development. In this technique, over 46 molecules are being used as monotherapy wherein the use of a single drug is used to treat a particular disorder.
Key questions answered in the report include
- What are the drug molecules in the various development stages for Influenza A?
- What are the companies that are currently involved in the drug development molecules for Influenza A?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.